LTBP-2 inhibitors are a specialized class of compounds designed to target and inhibit the activity of Latent Transforming Growth Factor Beta Binding Protein 2 (LTBP-2). LTBP-2 is a member of the LTBP family of proteins that play a critical role in the regulation of transforming growth factor-beta (TGF-β) signaling, a key pathway involved in cellular growth, differentiation, and extracellular matrix (ECM) formation. Unlike other members of the LTBP family, LTBP-2 does not directly bind to TGF-β but instead interacts with the ECM and other structural components within the cellular environment. Inhibiting LTBP-2 offers researchers a unique tool to study its distinct role in ECM organization, the modulation of cell-matrix interactions, and its broader impact on cell signaling pathways.
The use of LTBP-2 inhibitors in scientific research is particularly valuable for exploring the non-TGF-β related functions of this protein, which are less understood compared to other LTBP family members. By inhibiting LTBP-2, researchers can disrupt its interactions within the ECM, allowing for a closer examination of how these interactions influence tissue architecture, cell adhesion, and mechanical signaling within various cellular contexts. Additionally, LTBP-2 inhibitors help to unravel the complexities of ECM dynamics, shedding light on how alterations in ECM composition and structure can affect cellular behavior and tissue integrity. This class of inhibitors is essential for advancing our understanding of ECM biology, providing insights into the intricate networks that maintain cellular and tissue homeostasis. Through the study of LTBP-2 inhibitors, researchers can gain a deeper appreciation of the multifaceted roles that ECM components play in regulating cell function and the overall maintenance of cellular environments.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
May indirectly affect Latent Transforming Growth Factor Beta Binding Protein (LTBP) by targeting the TGF-β pathway. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
Another TGF-β inhibitor; could also indirectly influence Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Another MMP inhibitor; could also indirectly influence Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K/Akt/mTOR inhibitor; might indirectly modulate Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K/Akt/mTOR inhibitor; could also indirectly influence Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Targets mTOR and could thereby indirectly modulate Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Another EGFR inhibitor; may also indirectly affect Latent Transforming Growth Factor Beta Binding Protein (LTBP). | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
Smad3 inhibitor; could thereby indirectly affect Latent Transforming Growth Factor Beta Binding Protein (LTBP) via Smad-dependent signaling. | ||||||